ABCB1 single nucleotide polymorphisms (1236C < T, 2677G< T, and 3435C < T) do not affect transport activity of human P-glycoprotein

Pharmacogenetics and Genomics

Volumn 23, Issue 6, 2013, Pages 314-323

  Dickens, David ^a   Owen, Andrew ^a   Alfirevic, Ana ^a   Pirmohamed, Munir ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

1236C

Indexed keywords

CYCLOSPORIN; DIGOXIN; DIPYRIDAMOLE; ELACRIDAR; IMATINIB; LANIQUIDAR; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; TARIQUIDAR; VALSPODAR; VERAPAMIL;

ABCB 1 GENE; ANIMAL CELL; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG TRANSPORT; GENE; GENE EXPRESSION SYSTEM; HUMAN; HUMAN CELL; IC 50; NONHUMAN; OOCYTE; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSPORT KINETICS; XENOPUS LAEVIS;

ANIMALS; BENZAMIDES; BIOLOGICAL TRANSPORT; CACO-2 CELLS; DIGOXIN; HAPLOTYPES; HUMANS; INHIBITORY CONCENTRATION 50; MUTANT PROTEINS; OOCYTES; P-GLYCOPROTEIN; PIPERAZINES; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRIMIDINES; REPRODUCIBILITY OF RESULTS; XENOPUS LAEVIS;

XENOPUS LAEVIS;

EID: 84879128863     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328360d10c     Document Type: Article

References (46)

1. Tanigawara Y. Role of P-glycoprotein in drug disposition. Ther Drug Monit 2000; 22:137-140.
2. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, Von Richter O, Zundler J, Kroemer HK. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104:147-153.
3. Schinkel AH, Smit JJ, Van Tellingen O, Beijnen JH,Wagenaar E, Van Deemter L, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994; 77:491-502.
4. Leschziner GD, Andrew T, Pirmohamed M, Johnson MR. ABCB1 genotype and PGP expression, function and therapeutic drug response: A critical review and recommendations for future research. Pharmacogenomics J 2007; 7:154-179.
5. Leschziner G, Zabaneh D, Pirmohamed M, Owen A, Rogers J, Coffey AJ, et al. Exon sequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance. Pharmacogenet Genomics 2006; 16:439-450.
6. Chinn LW, Kroetz DL. ABCB1 pharmacogenetics: Progress, pitfalls, and promise. Clin Pharmacol Ther 2007; 81:265-269.
7. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM. A 'silent' polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315:525-528.
8. Maffioli M, Camos M, Gaya A, Hernandez-Boluda JC, Alvarez-Larran A, Domingo A, et al. Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia. Leuk Res 2011; 35:1014-1019.
9. Ni LN, Li JY, Miao KR, Qiao C, Zhang SJ, Qiu HR, Qian SX. Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med Oncol 2011; 28:265-269.
10. Fox E, Bates SE. Tariquidar (XR9576): A P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther 2007; 7:447-459.
11. Friedenberg WR, Rue M, Blood EA, Dalton WS, Shustik C, Larson RA, et al. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): A trial of the Eastern Cooperative Oncology Group. Cancer 2006; 106:830-838.
12. Abraham J, Edgerly M,Wilson R, Chen C, Rutt A, Bakke S, et al. A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Clin Cancer Res 2009; 15:3574-3582.
13. Bankstahl JP, Kuntner C, Abrahim A, Karch R, Stanek J, Wanek T, et al. Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET. J Nucl Med 2008; 49:1328-1335.
14. Pirmohamed M. Drug-drug interactions and adverse drug reactions: Separating the wheat from the chaff. Wien Klin Wochenschr 2010; 122:62-64.
15. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010; 9:215-236.
16. Agarwal S, Arya V, Zhang L. Review of P-gp inhibition data in recently approved new drug applications: Utility of the proposed [I1]/IC50 and [I2]/IC50 criteria in the P-gp decision tree. J Clin Pharmacol 2013; 53:228-233.
17. Jutabha P, Wempe MF, Anzai N, Otomo J, Kadota T, Endou H. Xenopus laevis oocytes expressing human P-glycoprotein: Probing trans-and cisinhibitory effects on [3H]vinblastine and [3H]digoxin efflux. Pharmacol Res 2010; 61:76-84.
18. Bakos E, Klein I, Welker E, Szabo K, Muller M, Sarkadi B, Varadi A. Characterization of the human multidrug resistance protein containing mutations in the ATP-binding cassette signature region. Biochem J 1997; 323 (Pt 3):777-783.
19. Hartkoorn RC, Kwan WS, Shallcross V, Chaikan A, Liptrott N, Egan D, et al. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics 2010; 20:112-120.
20. Wang HC, Beer B, Sassano D, Blume AJ, Ziai MR. Gene expression in Xenopus oocytes. Int J Biochem 1991; 23:271-276.
21. Chandler B, Almond L, Ford J, Owen A, Hoggard P, Khoo S, Back D. The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. J Acquir Immune Defic Syndr 2003; 33:551-556.
22. Martin P, Riley R, Back DJ, Owen A. Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells. Br J Pharmacol 2008; 153:805-819.
23. Elsby R, Surry DD, Smith VN, Gray AJ. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions. Xenobiotica 2008; 38:1140-1164.
24. Thomas J,Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: Implications for drug resistance. Blood 2004; 104:3739-3745.
25. Schinkel AH,Wagenaar E, Van Deemter L, Mol CA, Borst P. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995; 96:1698-1705.
26. Shu Y, Leabman MK, Feng B, Mangravite LM, Huang CC, Stryke D, et al. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci USA 2003; 100:5902-5907.
27. Janke D, Mehralivand S, Strand D, Godtel-Armbrust U, Habermeier A, Gradhand U, et al. 6-Mercaptopurine and 9-(2-phosphonyl-methoxyethyl) adenine (PMEA) transport altered by two missense mutations in the drug transporter gene ABCC4. Hum Mutat 2008; 29:659-669.
28. Siccardi M, D'avolio A, Nozza S, Simiele M, Baietto L, Stefani FR, et al. Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. Pharmacogenet Genomics 2010; 20:759-765.
29. Sobczak K, Bangel-Ruland N, Leier G, Weber WM. Endogenous transport systems in the Xenopus laevis oocyte plasma membrane. Methods 2010; 51:183-189.
30. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70: 189-199.
31. Morita N, Yasumori T, Nakayama K. Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. Biochem Pharmacol 2003; 65:1843-1852.
32. Kim DH, Sriharsha L, Xu W, Kamel-Reid S, Liu X, Siminovitch K, et al. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res 2009; 15:4750-4758.
33. Dulucq S, Bouchet S, Turcq B, Lippert E, Etienne G, Reiffers J, et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2008; 112:2024-2027.
34. Dulucq S, Preudhomme C, Guilhot F, Mahon FX. Response: Is there really a relationship between multidrug resistance gene (MDR1) polymorphisms and major molecular response to imatinib in chronic myeloid leukemia? Blood 2010; 116:6145-6146.
35. Gurney H,Wong M, Balleine RL, Rivory LP, Mclachlan AJ, Hoskins JM, et al. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin Pharmacol Ther 2007; 82:33-40.
36. Petain A, Kattygnarath D, Azard J, Chatelut E, Delbaldo C, Geoerger B, et al. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin Cancer Res 2008; 14:7102-7109.
37. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C > T affects mRNA stability. Pharmacogenet Genomics 2005; 15:693-704.
38. Verstuyft C, Strabach S, El-Morabet H, Kerb R, Brinkmann U, Dubert L, et al. Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. Clin Pharmacol Ther 2003; 73:51-60.
39. Wang EJ, Lew K, Casciano CN, Clement RP, Johnson WW. Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemother 2002; 46:160-165.
40. Kusunoki N, Takara K, Tanigawara Y, Yamauchi A, Ueda K, Komada F, et al. Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein. Jpn J Cancer Res 1998; 89:1220-1228.
41. Van Zuylen L, Verweij J, Nooter K, Brouwer E, Stoter G, Sparreboom A. Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin Cancer Res 2000; 6:2598-2603.
42. Van Zuylen L, Sparreboom A, Van Der Gaast A, Nooter K, Eskens FA, Brouwer E, et al. Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933. Eur J Cancer 2002; 38:1090-1099.
43. Bardelmeijer HA, Ouwehand M, Beijnen JH, Schellens JH, Van Tellingen O. Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice. Invest New Drugs 2004; 22:219-229.
44. Giri N, Agarwal S, Shaik N, Pan G, Chen Y, Elmquist WF. Substratedependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: Consideration of multiple binding sites in in vitro assay design. Drug Metab Dispos 2009; 37:560-570.
45. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 1993; 53:4595-4602.
46. Ward KW, Azzarano LM. Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9,10-dihydro-5- methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquino linyl)ethyl]phenyl]-4-acridine-carboxamide) in the mouse, rat, dog, and monkey. J Pharmacol Exp Ther 2004; 310:703-709.